Heart failure is a complex clinical syndrome that can be challenging to manage. In this program, we will discuss how pulmonary artery pressure monitoring can provide heart failure care teams with the clarity to optimize medical therapy, prevent heart failure hospitalizations and know when a patient may be ready for advanced therapies. We will discuss how new clinical data have supported this technology being approved for even more patients. Care teams will now have access to valuable presymptomatic data to slow the progression of heart failure sooner for their patients.
This Symposium is not part of the AAHFN official educational program and the sessions and content are not endorsed by AAHFNI. This Symposium is a promotional activity and is not approved for continuing education credit. The content and opinions expressed by presenters are those of the company, sponsor or presenter and not the AAHFN.
Monitoring pulmonary artery (PA) pressure daily, the CardioMEMS HF System gives you unique presymptomatic data that you do not get from any other remote hemodynamic monitor. This important data is an early indicator of worsening heart failure and can inform proactive treatment adjustments up to thirty days before weight gain, or other heart failure symptoms appear.²
Rx Only
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
CardioMEMS™ HF System Indications and Usage: The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.
CardioMEMS™ HF System Contraindications: The CardioMEMS™ HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.
CardioMEMS™ HF System Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolization, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax.
MAT-2206038 v2.0
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test
